Bone Marrow Transplantation

Article	Citations
When is a chimaera not a chimaera?	116
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)	93
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	75
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study	69
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)	68
Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes	60
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency	58
Prognostic impact of histopathologic features including histological grading and immunohistochemistry-positive cell counts in cytomegalovirus-gastrointestinal disease after allogeneic hematopoietic ce	53
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P919-P930)	42
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status	41
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma	41
Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults	38
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peri	38
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study	38
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma	38
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany	37
Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study	32
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia	31
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma	31
Cytokine release syndrome: implications for transplant outcomes in haploidentical and HLA-matched HSCT using PTCy	30
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients	30
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact	30
CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma	30
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from th	29
Palliative care involvement for pediatric hematopoietic cell transplant patients can enhance comfort-focused care at end of life without shortening survival duration	27

Randomized phase 2 study of digital life coaching during transplantation for myeloma	27
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation	26
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study	26
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey	26
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China	25
Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation	25
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the	25
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen	24
The effect of posttransplant cyclophosphamide on ocular graft-versus-host disease	24
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease	23
Which is older, Medicine or Wine?	23
Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients	23
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P762-P770)	23
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study	23
Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia	22
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O155)	22
An extraction pipeline for analysis of hematopoietic stem cell transplantation data	22
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell tr	22
The role of splenic irradiation prior to allogeneic hematopoietic stem transplantation in myelofibrosis: a review of the literature	22
Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma	22
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host diseas	22
Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation	22
Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy	21
The germline challenge in allogeneic transplantation: from donor selection to outcomes	21
Impact of center volume on outcomes in allogeneic hematopoietic cell transplantation for children	21
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation	21
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide	20
Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients	20
Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data	20
External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia	20
The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia	20
Bronchiectasis in patients with bronchiolitis obliterans syndrome: toward phenotyping BOS?	20
Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis	19
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination	19
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee	19
Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR	19
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale pr	19
Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient	19
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies	19
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT	19
Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT	19
Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance	18
Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party	18
Life 2.0: a comprehensive cross-sectional profiling of long-term allogeneic hematopoietic cell transplantation survivors compared to a matched general population cohort	18
Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric patients: a single center experience	18
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT	18
Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey	17
Efficacy of eltrombopag for treatment of thrombocytopenia in the setting of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis	17
Incidence of cardiovascular disease in healthy Swedish peripheral blood stem cell donors – a nationwide study	17
Autologous hematopoietic stem cell transplantation in severe, refractory stiff person syndrome: a case series	17

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O155-O159)	17
Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT	17
Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen	16
Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China	16
Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis	16
Return to school practices after hematopoietic cell transplantation: a survey of transplant centers in the United States	16
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for	16
Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms	16
Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT	16
Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRI	16
Donor lymphocyte infusion (DLI) post haploidentical stem cell transplantation (Haplo) with post-transplant cyclophosphamide (PTCy): crossing the human leukocyte antigen (HLA) barrier	16
Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Tran	16
GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation	16
Treosulfan-based double-alkylator conditioning in myelofibrosis: An Italian retrospective multicenter analysis	15
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Poster Session (P756-P761)	15
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT	15
Decision making on HSCT in patients with hemoglobinopathies; an EBMT Pediatric Diseases Working Party and Inborn Errors Working Party scenario-based survey on physicians’ perspectives	15
Physical performance before and after hematopoietic stem cell transplantation in pediatric patients: a potential role for prehabilitation	15
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Poster Session (P709-P715)	15
Wine, blood and religion	15
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities	15
CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease	15
Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an “outpatient” alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplant	15
Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease	15
Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study	14
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O167-O168)	14
Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP	14
Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia	14
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia	14
Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC	14
Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia	14
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial	14
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network m	14
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study	13
Role of consolidative radiotherapy in preventing relapses and subsequent salvage ASCT in early-stage classic Hodgkin lymphoma	13
Lung transplantation for pulmonary graft versus host disease: experience from a referral organ transplantation center	13
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome	13
Progressive multifocal leukoencephalopathy after CAR-T cell therapy	13
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures	13
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)	13
Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study	13
Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients	13
Post-thaw CD34+ cell recovery likely degraded under extreme graft platelet concentrations	13
Early administration of selected CD34 peripheral blood stem cell following bone marrow transplantation to prevent graft rejection: experience in haploidentical transplant for sickle cell disease	12
Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study	12
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Oral Session (O164-O169)	12
Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia	12
Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the	12
Gifts, wine and blood	12
Neglected tropical diseases (NTDs) and related infections in hematopoietic cellular therapy (HCT) in adults and children: a survey from the Infectious Diseases Working Party (IDWP) of the European Soc	12
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address	12
Outcome after Treosulfan-based conditioning in a real-world MDS cohort	12
aGvHDtrackR and cGvHDtrackR: shiny applications for graft versus host disease management and clinical data collection	11
Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study b	11
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marro	11
Chronic graft-versus-host disease: Current situation and unmet needs — A European position statement	11
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial	11
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplant	11
Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies	11
Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study	11
Late stenosis of the small intestine and colon, an atypical feature of chronic graft-versus-host disease. National retrospective study in French pediatric allograft centers	11
Tuberculosis after allogeneic hematopoietic stem cell transplantation: a decade nationwide case-control retrospective study in low-incidence country	11
Sexual function of adult long-term survivors and their partners after allogeneic hematopoietic cell transplantation in Europe (S-FAST): a study from the Transplant Complications Working Party and Nurs	11
Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBM	11
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome	11
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001-P755)	11
Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT	11
Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Socie	11
Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study	11
Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation	10
Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT	10
CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML	10
Toward functional cure in relapsed/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells	10
CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant	10
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL	10
Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation	10
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P590-P600)	10
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience	10
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transp	10
Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience	10

“30 years of global collaboration in transplantation and cellular therapy: WMDA’s commitment to donor safety, ethical standards, and equitable access”	10
Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation	10
Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir	10
Timing of achieving MRD negativity for B-ALL patients with IKZF1 alterations in CR1 may dictate transplant decision: Autologous versus Allogeneic HSCT	10
No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma	9
Favorable outcomes and the association between dynamic transfusion dependence and IPSS-M in MDS-h and MDS-LB patients undergoing allo-HSCT	9
Upfront memory T cell add-back with haploidentical TCRαβ-depleted graft in adults with haematological malignancies: a nationwide, multicentre, single-arm, prospective study	9
Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia	9
Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease	9
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma	9
Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group	9
Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan	9
Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates	9
Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT)	9
Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?	9
Successful use of defibrotide to treat allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy in pediatric patients: report from Chinese single center	9
Correction: Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin f	9
Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation	9
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address	9
Old age in patients and vines	9
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens	9
Age 60 or older is an independent predictor of outcomes after thiotepa-based autologous transplant in primary CNS lymphoma: a CIBMTR analysis	9
GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matche	9
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis	9
Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies	9
Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation	9
Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma	9
Microdissection testicular sperm extraction after pediatric allogeneic hematopoietic stem cell transplantation: a case series	9
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising committee	9
Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection	9
Psychosocial correlates of failure to complete hematopoietic stem cell transplants in a diverse population	9
Comparison of allo-SCT versus consolidation chemotherapy as post-remission therapy in acute lymphoblastic leukaemia aged ≥55 years	9
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial	8
“The antibiotic paradox” in allogeneic stem cell transplantation	8
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)	8
Pure white cell aplasia following allogeneic hematopoietic stem cell transplantation	8
Impact of body mass index on outcomes following allogeneic hematopoietic stem cell transplantation	8
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years o	8
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation	8
Graft engineering: how long can you wait, how low can you go, and pandemic readiness	8
Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era	8
Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation	8
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant	8
Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis	8
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy	8
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM	8
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey	8
Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation	8
Smoking cessation among blood or marrow transplant Survivors: a BMTSS Report	8
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation	8
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?	8
Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation	8
Hematopoietic stem cell transplantation in pediatric congenital erythropoietic porphyria: a French retrospective multicenter registry study on behalf of the Francophone Society of Bone Marrow Transpla	8
Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study	8
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity	8
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease	8
Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage	8
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide	8
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen	8
Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants	8
Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation	8
The effect of danger-associated molecular patterns on survival in acute graft versus host disease	8
Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment	8
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphoma	8
Correction: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee—Poster Session (P716-P724)	8
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party	8
Impact of graft CD34+ cell counts on hematological recovery in patients receiving post-transplant cyclophosphamide prophylaxis	8
Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease	8
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse	8
Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients	7
Acute kidney injury in peripheral blood haploidentical hematopoietic stem cell transplantation: should attract enough attention	7
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (E	7
Machine learning-based prediction of G-CSF-induced hematopoietic stem cell mobilization outcomes in healthy volunteers	7
Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India	7
Correction: Impact of custom prime on the PBSC collection efficiency and procedure outcome on Spectra Optia apheresis device by using the CMNC program in low-weight pediatric oncology patients. A sing	7
Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study	7
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Poster Sessions (NP001-NP079)	7
Jargon redux	7
Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party	7
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation:  Quality Management Group – Oral Session (O176)	7
Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major	7
Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party	7
Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience	7
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide	7
The use of mesenchymal stromal cells in steroid-refractory graft-versus-host disease after pediatric hematopoietic stem cell transplantation: a report of the Spanish group of stem cell transplantation	7
Bariatric surgery and allogeneic hematopoietic stem cell transplantation: a case series	7
Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro	7
Correction: Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?	7
Modified umbilical cord-blood transplantation for pediatric patients with mucopolysaccharidosis	7
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experie	7
Is myelo-ablative pretransplant conditioning really myelo-ablative: Implications for radiation and nuclear accidents?	7
Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis	7
Protection of haematopoietic progenitor cell donors: an updated overview of the European landscape	7
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis	7
Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium	7